CD8A and neoplasm: Morisada et al. demonstrated that conventionally fractionated RT, but not hypofractionated RT, reduced intratumoral CD8+ TIL effector activity, suppressed T-cell responses within tumor-draining lymph nodes, and mitigated the immune-enhancing effects of anti-PD-1 therapy in a syngeneic mouse oral carcinoma model [47].